BGLC · BioNexus Gene Lab Corp
$1.47
-0.02 (-1.34%)
At close · Sep 1
Going-concern doubt
— cleared Aug 14, 2026
The latest filing states the doubt was alleviated.
“These factors raise substantial doubt about the Company’s ability to continue as a going concern within one year of the date that the financial statements are issued. Management believes that the Company’s existing cash balance, together with its positive working capital position, will provide sufficient liquidity to fund operations and meet its obligations as they become due for at least the next twelve months from the date these condensed consolidated financial statements are issued.”View the 10-Q filed Aug 14, 2026
Market Cap
$4.37M
Shares
2.93M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$7.42M
-21.9%
FY2025
Net Income
-$2.98M
-86.7%
FY2025
Gross Margin
14.62%
+1.1pp
FY2025
Operating Margin
-39.93%
-23.4pp
FY2025
Diluted EPS
-$0.09
+45.8%
FY2024
Operating Cash Flow
-$1.84M
+12.2%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|---|
| $3.13M | $7.42M | $9.51M | $9.77M | $10.93M | $13.36M | $11.39M | $126.96K | $212.33K | |
| $9057 | — | — | $8877 | $7794 | — | — | — | — | |
| $2.74M | $6.34M | $8.22M | $8.44M | $9.67M | $11.1M | $9.67M | $71.07K | -$183.56K | |
| $385.89K | $1.09M | $1.29M | $1.33M | $1.26M | $2.27M | $1.72M | $55.89K | $28.77K | |
| — | 14.62% | 13.56% | 13.61% | 11.52% | 16.96% | 15.1% | 44.02% | 13.55% | |
| $54.13K | $50.67K | $47.51K | $54.98K | — | — | — | — | — | |
| $675.96K | $1.74M | $2.03M | $596.86K | — | — | — | — | — | |
| $1.25M | $1.54M | $1.83M | $2.44M | $1.73M | $1.28M | $1.33M | $356.64K | -$241.93K | |
| — | — | — | — | — | — | — | $41.71K | $40.61K | |
| $3.25M | $4.48M | $4.94M | -$4.41M | — | — | — | — | — | |
| -$2.56M | -$2.97M | -$1.57M | -$2.59M | -$291.18K | $1.06M | $1.27M | -$275.71K | $59.9K | |
| — | -39.93% | -16.55% | -26.54% | -2.66% | 7.9% | 11.18% | -217.17% | 28.21% | |
| — | — | — | — | — | — | — | -$233.99K | $100.51K | |
| $19.52K | — | — | $13.93K | $12.48K | — | — | — | — | |
| $398.38K | $432.12K | $2.07M | $486.04K | — | — | — | $29.24K | -$33.45K | |
| — | — | — | — | — | $0 | $3965 | $0 | — | |
| -$2.58M | -$2.98M | -$1.59M | -$2.61M | -$303.66K | $1.04M | — | — | — | |
| $0 | $0 | -$3494 | -$21.53K | -$52.31K | -$291.28K | — | $24.76K | -$33.45K | |
| -$2.58M | -$2.98M | -$1.6M | -$2.63M | -$355.97K | $751.57K | $1.09M | -$246.47K | $26.45K | |
| — | -40.2% | -16.81% | -26.91% | -3.26% | 5.62% | 9.61% | -194.14% | 12.46% | |
| -$2.9M | -$2.98M | -$1.6M | -$2.63M | — | — | — | -$246.47K | — | |
| -$2.59M | -$2.55M | -$1.48M | -$2.9M | -$664.77K | $517.63K | $1.24M | -$236.6K | -$14.57K | |
| USD/shares | — | — | -$0.09 | -$0.17 | — | — | — | — | — |
| shares | — | — | — | — | — | — | 10.29M | 8.64M | 6.63M |
| shares | — | — | 17.82M | 15.88M | — | — | 10.29M | 8.64M | 6.63M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 7.45×
EV/EBIT
—
P/E (TTM)
—
Peer medians compare against the 10 similar-size Specialty Chemicals companies (of 64 listed).
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Geography (USD)
| Component | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Malaysia | $5,829,401 | $7,455,906 | — |
| Maldives | $680,994 | $762,144 | — |
| Sri Lanka | $452,639 | $459,002 | — |
| Singapore | $240,757 | $572,027 | — |
| Indonesia | $114,867 | $138,300 | — |
| Bangladesh | $106,253 | $123,267 | — |
| BD | — | — | $538,062 |
| ID | — | — | $0 |
| LK | — | — | $87,026 |
| MA | — | — | $8,222,055 |
| MV | — | — | $637,186 |
| NG | — | — | $42,073 |
| SG | — | — | $244,404 |